Related Experiment Video
Updated: Dec 6, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Outcomes of Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Chronic Total Occlusion: A
Insights
Percutaneous coronary intervention for chronic total occlusion (CTO-PCI) may reduce mortality compared to optimal medical therapy alone. However, these benefits were mainly observed in observational studies, not randomized controlled trials, necessitating further research.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Concurrent chronic total occlusion (CTO) significantly predicts mortality.
- Percutaneous coronary intervention (PCI) for CTO has shown clinical benefits.
Purpose of the Study:
- To compare the outcomes of CTO-PCI versus optimal medical therapy (OMT) through a meta-analysis.
- To evaluate the impact of CTO-PCI on mortality, cardiac events, and stroke.
Main Methods:
- A meta-analysis of 16 studies (11,314 patients) published between 2006-2019.
- Searched PubMed, ClinicalTrials.gov, Google Scholar, and Cochrane Central Register.
- Analyzed mortality, cardiac deaths, myocardial re-infarction, MACE, stroke, and repeat PCI using random-effects models.
Main Results:
- CTO-PCI was associated with significantly lower mortality (OR: 0.45) and cardiac deaths (OR: 0.58) compared to OMT alone.
- These findings were primarily driven by observational studies; no significant differences were found in randomized controlled trials.
- No significant differences were observed in major adverse cardiac events, myocardial re-infarction, stroke, or repeat PCI.
Conclusions:
- CTO-PCI may reduce long-term mortality and cardiac deaths compared to OMT, but this is primarily based on observational data.
- The benefits of CTO-PCI require confirmation from further randomized controlled trials.
- More research is needed to fully evaluate the long-term outcomes of CTO-PCI versus OMT.
Abstract:
The presence of concurrent chronic total occlusion (CTO) is a strong predictor for both short-term and long-term mortality. Successful percutaneous coronary intervention (PCI) of CTO has been associated with clinical benefit. We sought to perform a meta-analysis comparing CTO-PCI versus optimal medical therapy. PubMed, ClinicalTrials.gov, Google scholar and the Cochrane Central Register of Controlled Trials were searched for studies published from 2006 to 2019. A total of 16 studies, with 11,314 patients were included. We analyzed data on mortality, cardiac deaths, myocardial re-infarction, major adverse cardiac events, stroke, and repeat CTO-PCI using random-effects models. The odds ratios (OR) with 95% confidence interval (CI) were computed and P < 0.05 was considered as a level of significance. Compared with medical therapy alone, CTO-PCI was associated with lower mortality (OR: 0.45, CI: 0.32-0.63, P < 0.00001) and cardiac deaths (OR: 0.58, CI: 0.38-0.89, P = 0.01). These results were primarily driven by observational studies with no difference observed in randomized controlled trials. There was no significant difference in the incidence of major adverse cardiac events (OR: 0.71, CI: 0.48-1.05, P = 0.54), myocardial re-infarction (OR: 0.71, CI: 0.48-1.05, P = 0.54), stroke (OR: 0.61, CI: 0.32-1.17, P = 0.14, and repeat PCI (OR: 1.28, CI: 0.91-1.78, P = 0.16). This meta-analysis shows lower long-term mortality and cardiac deaths in CTO-PCI group as compared to OMT driven by observational studies with no difference observed in randomized controlled trials. Further randomized trials are needed to confirm these findings and evaluate long term results.
More Related Videos
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Acute Coronary Syndrome III: Diagnostic Studies

